Show simple item record

dc.contributor.authorKiely, Patrick
dc.contributor.authorBusby, Amanda
dc.contributor.authorNikiphorou, Elena
dc.contributor.authorSullivan, Keith
dc.contributor.authorWalsh, David
dc.contributor.authorCreamer, Paul
dc.contributor.authorDixey, Josh
dc.contributor.authorYoung, Keith
dc.date.accessioned2019-08-07T00:59:52Z
dc.date.available2019-08-07T00:59:52Z
dc.date.issued2019-05-05
dc.identifier.citationKiely , P , Busby , A , Nikiphorou , E , Sullivan , K , Walsh , D , Creamer , P , Dixey , J & Young , K 2019 , ' Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts ' , BMJ Open , vol. 9 , no. 5 , e028466 . https://doi.org/10.1136/bmjopen-2018-028466
dc.identifier.issn2044-6055
dc.identifier.otherORCID: /0000-0002-0545-0276/work/133568265
dc.identifier.urihttp://hdl.handle.net/2299/21548
dc.description© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
dc.description.abstractObjectives To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-ILD) in two early RA inception cohorts with a focus on methotrexate (MTX) exposure. Design Multicenter prospective early RA inception cohort studies; the early RA study (ERAS) and the early RA network (ERAN) Setting Secondary care, ERAS 9 centers, ERAN 23 centers in England, Wales and the Republic of Ireland Participants Patients with new diagnosis of RA, n=2701.Standardised data including demographics, drug therapies and clinical outcomes including the presence of RA-ILD were collected at baseline, within 3- 6 months, at 12 months and annually thereafter. Primary and secondary outcome measures Primary outcome was the association of MTX exposure on RA-ILD diagnosis. Secondary outcomes were the association of demographic, comorbid and RA specific factors on RA-ILD diagnosis and the association of MTX exposure on time to RA-ILD diagnosis. Results Of 92 eligible ILD cases, 39 occurred in 1578 (2.5%) MTX exposed and 53 in 1114 (4.8%) non-MTX exposed cases. The primary analysis of RA-ILD cases only developing after any csDMARD treatment (n=67) showed MTX exposure not to be associated with incident RA-ILD (O.R. 0.85 CI 0.49, 1.49 p=0.578) and a non-significant trend for delayed ILD diagnosis (O.R. 0.54 CI 0.28, 1.06 p=0.072). In an extended analysis including RA-ILD cases present at RA diagnosis (n=92), MTX exposure was associated with a significantly reduced risk of incident RA-ILD (O.R. 0.48, CI 0.3, 0.79 p=0.004) and longer time to ILD diagnosis (O.R. 0.41, CI 0.23, 0.75 p=0.004). Other independent baseline associations with incident RA-ILD were higher age of RA onset, ever smoking, male gender, rheumatoid nodules and longer time from first RA symptom to first out-patient visit. Conclusions MTX treatment was not associated with an increased risk of RA-ILD diagnosis. On the contrary evidence suggested that MTX may delay the onset of ILD.en
dc.format.extent3313782
dc.format.extent3293603
dc.format.extent1493444
dc.language.isoeng
dc.relation.ispartofBMJ Open
dc.subjectinterstitial lung disease
dc.subjectmethotrexate
dc.subjectrheumatoid arthritis
dc.subjectMedicine(all)
dc.titleIs incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohortsen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth Research Methods Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionDepartment of Psychology and Sports Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85065424337&partnerID=8YFLogxK
rioxxterms.versionofrecord10.1136/bmjopen-2018-028466
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record